open access

Vol 9, No 3 (2018)
Review paper
Published online: 2018-10-17
Get Citation

Renal amyloidosis

Wojciech Wołyniec12, Agnieszka Perkowska-Ptasińska1, Alicja Dębska-Ślizień3, Tomasz Liberek3, Magdalena Durlik1
DOI: 10.5603/Hem.2018.0028
·
Hematologia 2018;9(3):208-221.
Affiliations
  1. Klinika Medycyny Transplantacyjnej, Nefrologii i Chorób Wewnętrznych, Instytut Transplantologii im. Prof. Tadeusza Orłowskiego, Warszawski Uniwersytet Medyczny
  2. Gdański Uniwersytet Medyczny, Klinika Chorób Zawodowych, Metabolicznych i Wewnętrznych, Powstania Styczniowego 9b, 81-519 Gdynia, Poland
  3. Gdański Uniwersytet Medyczny, Katedra i Klinika Nefrologii, Transplantologii i Chorób Wewnętrznych, Smoluchowskiego 9, 80-214 Gdańsk, Poland

open access

Vol 9, No 3 (2018)
REVIEW ARTICLES
Published online: 2018-10-17

Abstract

Kidney amyloid deposition is one of the most common and most severe manifestations of systemic amyloidosis. Since kidney involvement occurs in almost each type of amyloidosis, proteinuria and GFR (glomerular filtration rate) decrease are often among the first symptoms of this disease. Kidney involvement is, beside heart failure, a major prognostic factor. The most typical presentation is isolated nephrotic syndrome, especially in two most common types of the disease: AA and AL amyloidoses. The less common manifestation is chronic renal failure, which typically occurs in the acquired types of amyloidosis (ALECT2, AApoAIV), but also in several hereditary genetic forms. In the case of renal involvement, kidney biopsy is of major significance: it allows not only for amyloidosis recognition, but also for further specification of its type. Currently there are methods allowing for reduction in the amyloidogenic protein release and amyloid deposition, also in kidney tissue. Due to the effective treatment, proteinuria reduction and slowdown of kidney failure progression became possible. In the case of the successful control of amyloid production, patients with end-stage renal failure can be qualified for kidney transplantation.

Abstract

Kidney amyloid deposition is one of the most common and most severe manifestations of systemic amyloidosis. Since kidney involvement occurs in almost each type of amyloidosis, proteinuria and GFR (glomerular filtration rate) decrease are often among the first symptoms of this disease. Kidney involvement is, beside heart failure, a major prognostic factor. The most typical presentation is isolated nephrotic syndrome, especially in two most common types of the disease: AA and AL amyloidoses. The less common manifestation is chronic renal failure, which typically occurs in the acquired types of amyloidosis (ALECT2, AApoAIV), but also in several hereditary genetic forms. In the case of renal involvement, kidney biopsy is of major significance: it allows not only for amyloidosis recognition, but also for further specification of its type. Currently there are methods allowing for reduction in the amyloidogenic protein release and amyloid deposition, also in kidney tissue. Due to the effective treatment, proteinuria reduction and slowdown of kidney failure progression became possible. In the case of the successful control of amyloid production, patients with end-stage renal failure can be qualified for kidney transplantation.
Get Citation

Keywords

nephrotic syndrome; kidney biopsy; amyloid precursor protein; typing of amyloid deposits

About this article
Title

Renal amyloidosis

Journal

Hematology in Clinical Practice

Issue

Vol 9, No 3 (2018)

Article type

Review paper

Pages

208-221

Published online

2018-10-17

DOI

10.5603/Hem.2018.0028

Bibliographic record

Hematologia 2018;9(3):208-221.

Keywords

nephrotic syndrome
kidney biopsy
amyloid precursor protein
typing of amyloid deposits

Authors

Wojciech Wołyniec
Agnieszka Perkowska-Ptasińska
Alicja Dębska-Ślizień
Tomasz Liberek
Magdalena Durlik

References (70)
  1. Nuvolone M, Merlini G. Systemic amyloidosis: novel therapies and role of biomarkers. Nephrol Dial Transplant. 2017; 32(5): 770–780.
  2. Wechalekar AD, Gillmore JD, Hawkins PN. Systemic amyloidosis. Lancet. 2016; 387(10038): 2641–2654.
  3. Dember LM. Amyloidosis-associated kidney disease. J Am Soc Nephrol. 2006; 17(12): 3458–3471.
  4. Picken MM. Amyloidosis – where are we now and where are we heading? Arch Pathol Lab Med. 2010; 134(4): 545–551.
  5. Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril proteins and amyloidosis: chemical identification and clinical classification International Society of Amyloidosis 2016 Nomenclature Guidelines. Amyloid. 2016; 23(4): 209–213.
  6. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003; 349(6): 583–596.
  7. Harris DL, King E, Ramsland PA, et al. Binding of nascent collagen by amyloidogenic light chains and amyloid fibrillogenesis in monolayers of human fibrocytes. J Mol Recognit. 2000; 13(4): 198–212, doi: 10.1002/1099-1352(200007/08)13:4<198::AID-JMR499>3.0.CO;2-D.
  8. Milani P, Merlini G, Palladini G. Kidney Involvement in Light Chain Amyloidosis. Journal of Onco-Nephrology. 2018; 1(2): 110–119.
  9. Mehtat Ünlü Ş, Özsan H, Sarıoğlu S. The Scope of Kidney Affection in Monoclonal Gammopathies at All Levels of Clinical Significance. Turk J Haematol. 2017; 34(4): 282–288.
  10. Lachmann HJ, Goodman HJB, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007; 356(23): 2361–2371.
  11. Ojile N, Brake M. Urethral Amyloidosis in a Patient with IgA Nephropathy After Renal Transplant. Cureus. 2017; 9(5): e1296.
  12. Nienhuis HLA, Bijzet J, Hazenberg BPC. The Prevalence and Management of Systemic Amyloidosis in Western Countries. Kidney Dis (Basel). 2016; 2(1): 10–19.
  13. Ayar Y, Ersoy A, Oksuz MF, et al. Clinical outcomes and survival in AA amyloidosis patients. Rev Bras Reumatol Engl Ed. 2017; 57(6): 535–544.
  14. Murakami Y, Hattori S, Sugiyama F, et al. A case of primary (AL) amyloidosis with predominantly vascular amyloid deposition in the kidney. CEN Case Rep. 2015; 4(2): 151–156.
  15. Pinney JH, Smith CJ, Taube JB, et al. Systemic amyloidosis in England: an epidemiological study. Br J Haematol. 2013; 161(4): 525–532.
  16. Krupa B, Stolarczyk J. Clinical and morphological aspects of renal amyloidosis and uremia. Pol Arch Med Wewn. 1961; 31: 107–118.
  17. Larsen CP, Ismail W, Kurtin PJ, et al. Leukocyte chemotactic factor 2 amyloidosis (ALECT2) is a common form of renal amyloidosis among Egyptians. Mod Pathol. 2016; 29(4): 416–420.
  18. Real de Asúa D, Costa R, Contreras MM, et al. Clinical characteristics of the patients with systemic amyloidosis in 2000–2010. Rev Clin Esp (Barc). 2013; 213(4): 186–193.
  19. von Hutten H, Mihatsch M, Lobeck H, et al. Prevalence and origin of amyloid in kidney biopsies. Am J Surg Pathol. 2009; 33(8): 1198–1205.
  20. Liberek T, Cackowska M, Krol E, et al. Sp151renal amyloidosis – a common cause of nephrotic syndrome in older patients. Nephrology Dialysis Transplantation. 2017; 32(Suppl 3): iii155–iii155.
  21. Panizo N, Rivera F, López-Gómez JM. Spanish Registry of Glomerulonephritis. Decreasing incidence of AA amyloidosis in Spain. Eur J Clin Invest. 2013; 43(12): 767–773.
  22. Scarpioni R, Ricardi M, Albertazzi V, et al. Dialysis-related amyloidosis: challenges and solutions. Int J Nephrol Renovasc Dis. 2016; 9: 319–328.
  23. Cornwell GG, Murdoch WL, Kyle RA, et al. Frequency and distribution of senile cardiovascular amyloid. A clinicopathologic correlation. Am J Med. 1983; 75(4): 618–623.
  24. Sethi S, Theis JD. Pathology and diagnosis of renal non-AL amyloidosis. J Nephrol. 2018; 31(3): 343–350.
  25. Said SM, Sethi S, Valeri AM, et al. Characterization and outcomes of renal leukocyte chemotactic factor 2-associated amyloidosis. Kidney Int. 2014; 86(2): 370–377.
  26. Nasr SH, Dogan A, Larsen CP. Leukocyte Cell-Derived Chemotaxin 2-Associated Amyloidosis: A Recently Recognized Disease with Distinct Clinicopathologic Characteristics. Clin J Am Soc Nephrol. 2015; 10(11): 2084–2093.
  27. Mereuta OM, Theis JD, Vrana JA, et al. Leukocyte cell-derived chemotaxin 2 (LECT2)-associated amyloidosis is a frequent cause of hepatic amyloidosis in the United States. Blood. 2014; 123(10): 1479–1482.
  28. Murphy CL, Wang S, Kestler D, et al. Leukocyte chemotactic factor 2 (LECT2)-associated renal amyloidosis: a case series. Am J Kidney Dis. 2010; 56(6): 1100–1107.
  29. Larsen CP, Kossmann RJ, Beggs ML, et al. Clinical, morphologic, and genetic features of renal leukocyte chemotactic factor 2 amyloidosis. Kidney Int. 2014; 86(2): 378–382.
  30. Lu XJ, Chen J, Yu CH, et al. LECT2 protects mice against bacterial sepsis by activating macrophages via the CD209a receptor. J Exp Med. 2013; 210(1): 5–13.
  31. Perkowska-Ptasinska A, Bartczak A, Wagrowska-Danilewicz M, et al. Polish Society of Nephrology. Clinicopathologic correlations of renal pathology in the adult population of Poland. Nephrol Dial Transplant. 2017; 32(Suppl 2): ii209–ii218.
  32. Perkowska-Ptasinska A, Deborska-Materkowska D, Bartczak A, et al. Kidney disease in the elderly: biopsy based data from 14 renal centers in Poland. BMC Nephrol. 2016; 17(1): 194.
  33. Eirin A, Irazabal MV, Gertz MA, et al. Clinical features of patients with immunoglobulin light chain amyloidosis (AL) with vascular-limited deposition in the kidney. Nephrol Dial Transplant. 2012; 27(3): 1097–1101.
  34. Dasari S, Amin MdS, Kurtin PJ, et al. Clinical, biopsy, and mass spectrometry characteristics of renal apolipoprotein A-IV amyloidosis. Kidney Int. 2016; 90(3): 658–664.
  35. Tsukanov J, Fabbro ED. Palliative care and symptom management in amyloidosis: A review. Curr Probl Cancer. 2016; 40(5–6): 220–228.
  36. Liangos O, Buettner-Herold M, Ketteler M, et al. Atypical case of AL amyloidosis with urinary erythrocyte casts. Clin Nephrol Case Stud. 2015; 3: 19–24.
  37. Yilmaz M, Unsal A, Sokmen M, et al. Renal involvement in AA amyloidosis: clinical outcomes and survival. Kidney Blood Press Res. 2013; 37(1): 33–42.
  38. Bhat A, Selmi C, Naguwa SM, et al. Currents concepts on the immunopathology of amyloidosis. Clin Rev Allergy Immunol. 2010; 38(2–3): 97–106.
  39. Jamroziak K, Milani P, Puła B. Diagnostyka i leczenie amyloidozy AL. 5603/ Hem. 2018; 9(3): 0021.
  40. Rezk T, Lachmann HJ, Fontana M, et al. Prolonged renal survival in light chain amyloidosis: speed and magnitude of light chain reduction is the crucial factor. Kidney Int. 2017; 92(6): 1476–1483.
  41. Shah M, Perazella M. AKI in Multiple Myeloma: Paraproteins, Metabolic Disturbances, and Drug Toxicity. J Onco-Nephrol. 2017; 1(3): 188–197.
  42. Leung N, Drosou ME, Nasr SH. Dysproteinemias and Glomerular Disease. Clin J Am Soc Nephrol. 2018; 13(1): 128–139.
  43. Sethi S, Theis JD, Leung N, et al. Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin J Am Soc Nephrol. 2010; 5(12): 2180–2187.
  44. Wiland P, Wojtala R, Goodacre J, et al. The prevalence of subclinical amyloidosis in Polish patients with rheumatoid arthritis. Clin Rheumatol. 2004; 23(3): 193–198.
  45. Ichikawa K, Konta T, Sato H, et al. The clinical and pathological characteristics of nephropathies in connective tissue diseases in the Japan Renal Biopsy Registry (J-RBR). Clin Exp Nephrol. 2017; 21(6): 1024–1029.
  46. Basturk T, Ozagari A, Ozturk T, et al. Crohn's disease and secondary amyloidosis: early complication? A case report and review of the literature. J Ren Care. 2009; 35(3): 147–150.
  47. Altindal M, Turkmen E, Yildirim T, et al. Kidney transplantation for end-stage renal disease secondary to familial Mediterranean fever. Clin Transplant. 2016; 30(7): 787–790.
  48. Rowczenio DM, Gomes SM, Aróstegui JI, et al. Late-Onset Cryopyrin-Associated Periodic Syndromes Caused by Somatic NLRP3 Mosaicism-UK Single Center Experience. Front Immunol. 2017; 8: 1410.
  49. Pearson KT, Vota S. Amyloidosis and its management: Amyloid neuropathies. Curr Probl Cancer. 2016; 40(5–6): 198–208.
  50. Lipowska M, Rowczenio D, Gilbertson J, et al. Transthyretin-related Familial Amyloid Polyneuropathy (TTR-FAP) caused by a very rare, de novo mutation in a Polish patient. Orphanet J Rare Dis. 2015; 10(Suppl 1): P25.
  51. Rona G, Pasaoglu L, Ozkayar N, et al. Functional evaluation of secondary renal amyloidosis with diffusion-weighted MR imaging. Ren Fail. 2016; 38(2): 249–255.
  52. Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis. Circulation. 2016; 133(24): 2404–2412.
  53. Rowczenio D, Tennent GA, Gilbertson J, et al. Clinical characteristics and SAP scintigraphic findings in 10 patients with AGel amyloidosis. Amyloid. 2014; 21(4): 276–281.
  54. Linke RP. On typing amyloidosis using immunohistochemistry. Detailled illustrations, review and a note on mass spectrometry. Prog Histochem Cytochem. 2012; 47(2): 61–132.
  55. Fernández de Larrea C, Verga L, Morbini P, et al. A practical approach to the diagnosis of systemic amyloidoses. Blood. 2015; 125(14): 2239–2244.
  56. Vinicki JP, Pellet SC, De Rosa G, et al. Analysis of 65 Renal Biopsies From Patients With Rheumatoid Arthritis (1976–2015): Change in Treatment Strategies Decreased Frequency and Modified Histopathological Findings. J Clin Rheumatol. 2015; 21(7): 335–340.
  57. Esatoglu SN, Hatemi G, Ugurlu S, et al. Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy: A STROBE-compliant observational study. Medicine (Baltimore). 2017; 96(34): e7859.
  58. Sekijima Y. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry. 2015; 86(9): 1036–1043.
  59. Ward JE, Ren R, Toraldo G, et al. Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. Blood. 2011; 118(25): 6610–6617.
  60. Dember LM, Hawkins PN, Hazenberg BPC, et al. Eprodisate for AA Amyloidosis Trial Group. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med. 2007; 356(23): 2349–2360.
  61. Lu C, Zuo Ke, Lu Y, et al. Apolipoprotein A-1-related amyloidosis 2 case reports and review of the literature. Medicine (Baltimore). 2017; 96(39): e8148.
  62. Bodin K, Ellmerich S, Kahan MC, et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature. 2010; 468(7320): 93–97.
  63. Leung N. My Patient with Monoclonal Gammopathy of Undetermined Significance has a Kidney Problem. J Onco-Nephrol. 2018; 1(1): 18–23.
  64. Sattianayagam PT, Gibbs SDJ, Pinney JH, et al. Solid organ transplantation in AL amyloidosis. Am J Transplant. 2010; 10(9): 2124–2131.
  65. Ameer GA, Grovender EA, Ploegh H, et al. A novel immunoadsorption device for removing beta2-microglobulin from whole blood. Kidney Int. 2001; 59(4): 1544–1550.
  66. Gejyo F, Amano I, Ando T, et al. Society of β2-Microglobulin Adsorption Therapy. Survey of the effects of a column for adsorption of β2-microglobulin in patients with dialysis-related amyloidosis in Japan. Ther Apher Dial. 2013; 17(1): 40–47.
  67. Pinney JH, Lachmann HJ, Sattianayagam PT, et al. Renal transplantation in systemic amyloidosis-importance of amyloid fibril type and precursor protein abundance. Am J Transplant. 2013; 13(2): 433–441.
  68. Ben-Chetrit E, Levy M. Reproductive system in familial Mediterranean fever: an overview. Ann Rheum Dis. 2003; 62(10): 916–919.
  69. Turgal M, Selcuk I, Ozyuncu O. Pregnancy outcome of five patients with renal amyloidosis regarding familial Mediterranean fever. Ren Fail. 2014; 36(2): 306–308.
  70. Wołyniec W, Szafran-Dobrowolska J, Winnicka L, et al. Successful pregnancy in the patient with AA amyloidosis complicating Crohn's disease. Nefrol Dializoter Pol. 2017; 21(4): 176–178.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.